Consistent with the CRC cell line data, BETi treatment reduced phospho-AKT level, increased total p21 protein and reduced the level of phosphorylated p21 at Thr145 in the PDO model (Fig. 7H). This evidence concerns the gene AKT1 and colorectal carcinoma.